Welcome to our dedicated page for Phibro Animal Health Corporation news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health Corporation stock.
Phibro Animal Health Corporation (Class A, symbol: PAHC) is a leading global company specializing in animal health and mineral nutrition. With over 40 years of experience, Phibro is dedicated to meeting the rising demand for animal protein by focusing solely on animals used in food production. The company offers a comprehensive range of products for poultry, swine, beef and dairy cattle, and aquaculture.
Phibro's core business involves the development, manufacturing, and marketing of products designed to prevent, control, and treat animal diseases, enhance nutrition, and contribute to balanced mineral nutrition. Their product portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines. The company's operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products, with the Animal Health segment being the primary revenue driver.
In the fiscal year ending June 30, 2017, Phibro reported net sales of $764 million. The company employs over 1,400 professionals who are committed to delivering value-based solutions to livestock producers, helping them maintain and enhance the health of their animals. Phibro's products are sold both in the United States and internationally, demonstrating its significant global footprint.
Recent achievements and ongoing projects by Phibro include the development of new vaccines and nutritional specialties aimed at improving animal health and productivity. The company continues to partner with various stakeholders in the livestock industry to innovate and provide sustainable solutions.
Phibro's financial condition remains robust, supported by consistent revenue streams from its diversified product offerings. The company’s focus on research and development underscores its commitment to advancing animal health technologies and addressing the evolving needs of the livestock industry.
For the latest news and updates, Phibro Animal Health Corporation remains a key player in the animal health sector, reflecting its dedication to enhancing the well-being of food animals globally.
Phibro Animal Health Corporation (NASDAQ:PAHC) reported Q3 FY2021 net sales of $212 million, a marginal increase of less than 1% year-over-year. Net income fell to $12 million, a decrease of 10%, with diluted EPS at $0.30, down by 9%. For the nine-month period, net sales reached $613 million, up slightly, while net income surged by 34% to $37 million. Adjusted EBITDA for Q3 declined by 7% to $28 million. The company received EU GMP approval for a new vaccine facility in Ireland and sees potential for a strong Q4. Financial guidance suggests Q4 net sales between $213-217 million.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend is payable on June 23, 2021, to shareholders on record as of June 2, 2021. Phibro Animal Health is a global developer and manufacturer of animal health and nutrition products aimed at promoting sustainable livestock production.
Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its third quarter financial results on May 6, 2021, after market close. A conference call and webcast will follow on May 7, 2021, at 9:00 AM Eastern Time. Interested parties can access the call via phone or online, with a replay available two hours post-event. Phibro specializes in developing and supplying a range of animal health and mineral nutrition products aimed at supporting livestock health and sustainability. For details, visit investors.pahc.com.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Bank of America Securities 2021 Virtual Healthcare Conference. The event is scheduled for Tuesday, May 11, 2021, at 4:15 PM ET. Key executives including Chairman and CEO Jack Bendheim, CFO Damian Finio, and Executive VP Daniel Bendheim will address analysts and investors. The live audio presentation will be accessible on the Phibro Investor Relations Website, with a replay available post-event.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Barclays Virtual Global Healthcare Conference on March 10, 2021, at 3:35 PM Eastern Time. The company's Chairman and CEO, Jack Bendheim, along with CFO Damian Finio, will address financial analysts and investors during the session. Interested parties can access the live audio presentation on the Phibro Investor Relations Website, with a replay available afterward. Phibro focuses on animal health and mineral nutrition products to support sustainable livestock practices.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Bank of America Merrill Lynch 2021 Virtual Animal Health Summit on February 25, 2021. During the event, Chairman Jack Bendheim and CFO Damian Finio will address financial analysts and investors at 12:40 PM Eastern Time. The live audio presentation can be accessed on the company's Investor Relations website, with an archived replay available afterward. Phibro focuses on animal health and nutrition products, aimed at supporting sustainable livestock production.
Phibro Animal Health Corporation (NASDAQ:PAHC) reported its second-quarter financial results for the period ending December 31, 2020. Net sales reached $206 million, down 4% from the previous year, while net income improved to $13 million, an 8% increase. Diluted EPS increased by 10% to $0.32. The company noted challenges in international demand, particularly in China and Latin America. Despite sales declines, gross profit slightly improved. For Q3 2021, Phibro projects net sales between $205-208 million and net income of $11-12 million.
The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on March 24, 2021, to stockholders of record as of the close of business on March 3, 2021. The company focuses on developing and supplying animal health and nutrition products, assisting veterinarians and farmers in producing healthy food sustainably.
Phibro Animal Health Corporation (NASDAQ: PAHC) is set to release its second-quarter financial results on February 3, 2021, post-market close. A conference call and webcast will follow on February 4, 2021, at 9:00 AM ET, allowing stakeholders to engage with management. Interested parties can access the presentation via their investor relations website. Phibro focuses on providing a diverse range of animal health and mineral nutrition products, supporting sustainable food production with fewer natural resources.
Phibro Animal Health Corporation (NASDAQ:PAHC) reported its Q1 2020 results with net sales of $195 million, a 3% increase year-over-year and net income rising to $12 million, up from $2.5 million. Diluted EPS reached $0.30, an increase of $0.24. The company noted strong performance in its core Animal Health segment, particularly in nutritional specialty products and vaccines, while Mineral Nutrition saw a decline. The outlook for Q2 forecasts net sales of about $205 million, reflecting ongoing recovery in the animal production industry.
FAQ
What is the current stock price of Phibro Animal Health Corporation (PAHC)?
What is the market cap of Phibro Animal Health Corporation (PAHC)?
What does Phibro Animal Health Corporation do?
Which animals does Phibro's products cater to?
What are the main product categories of Phibro Animal Health Corporation?
How many employees does Phibro Animal Health Corporation have?
How much revenue did Phibro report for the fiscal year ending June 30, 2017?
What are the primary segments of Phibro's operations?
Where does Phibro sell its products?
What recent projects is Phibro involved in?
Who are Phibro's primary customers?
What drives Phibro's revenue?
